Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.

MLA

Inohara, Taku, et al. “Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.” JAMA: Journal of the American Medical Association, vol. 320, no. 21, Dec. 2018, pp. 2231–41. EBSCOhost, https://doi.org/10.1001/jama.2018.18077.

APA

Inohara, T., Manandhar, P., Kosinski, A. S., Matsouaka, R. A., Kohsaka, S., Mentz, R. J., Thourani, V. H., Carroll, J. D., Kirtane, A. J., Bavaria, J. E., Cohen, D. J., Kiefer, T. L., Gaca, J. G., Kapadia, S. R., Peterson, E. D., & Vemulapalli, S. (2018). Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA: Journal of the American Medical Association, 320(21), 2231–2241. https://doi.org/10.1001/jama.2018.18077

Chicago

Inohara, Taku, Pratik Manandhar, Andrzej S. Kosinski, Roland A. Matsouaka, Shun Kohsaka, Robert J. Mentz, Vinod H. Thourani, et al. 2018. “Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.” JAMA: Journal of the American Medical Association 320 (21): 2231–41. doi:10.1001/jama.2018.18077.